Antibacterial activity of paroxetine against Staphylococcus aureus and possible mechanisms of action

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Boswihi SS, Udo EE. Methicillin-resistant Staphylococcus aureus: an update on the epidemiology, treatment options and infection control. Curr. Med. Res. Pract. 8(1), 18–24 (2018).
  Google Scholar
• 2. Lakhundi S, Zhang K. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin. Microbiol. Rev. 31(4), e00020-18 (2018).
  MedlineGoogle Scholar
• 3. Turner NA, Sharma-Kuinkel BK, Maskarinec SA et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat. Rev. Microbiol. 17(4), 203–218 (2019).
  Medline CASGoogle Scholar
• 4. Wang X, Shen Y, Huang W, Zhou Y. Characterisation of community-acquired Staphylococcus aureus causing skin and soft tissue infections in a children’s hospital in Shanghai, China. Epidemiol. Infect. 147, e323 (2019).
  Medline CASGoogle Scholar
• 5. Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program. Open Forum Infect. Dis. 6(Suppl. 1), S47–S53 (2019).
  MedlineGoogle Scholar
• 6. Tacconelli E, Carrara E, Savoldi A et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18(3), 318–327 (2018). • MRSA belongs to the WHO high-priority list for research and development of new antibiotics.
  MedlineGoogle Scholar
• 7. Jarada TN, Rokne JG, Alhajj R. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. J. Cheminform. 12(1), 46 (2020).
  Medline CASGoogle Scholar
• 8. Barbarossa A, Rosato A, Corbo F et al. Non-antibiotic drug repositioning as an alternative antimicrobial approach. Antibiotics 11(6), 816 (2022).
  CASGoogle Scholar
• 9. Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat. Microbiol. 4(4), 565–577 (2019).
  Medline CASGoogle Scholar
• 10. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev. 7(1), 25–47 (2001).
  Medline CASGoogle Scholar
• 11. Foletto VS, Serafin MB, Bottega A et al. Repositioning of fluoxetine and paroxetine: study of potential antibacterial activity and its combination with ciprofloxacin. Med. Chem. Res. 29(3), 556–563 (2020).
  CASGoogle Scholar
• 12. Foletto VS, da Rosa TF, Serafin MB et al. Repositioning of antidepressant drugs and synergistic effect with ciprofloxacin against multidrug-resistant bacteria. World J. Microbiol. Biotechnol. 37(3), 53 (2021).
  Medline CASGoogle Scholar
• 13. Kalaycı S, Demirci S, Sahin F. Antimicrobial properties of various psychotropic drugs against broad range microorganisms. Curr. Psychopharmacol. 3(3), 195–202 (2014).
  CASGoogle Scholar
• 14. Munoz-Bellido JL, Munoz-Criado S, Garcìa-Rodrìguez JA. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int. J. Antimicrob. Agents 14(3), 177–180 (2000).
  Medline CASGoogle Scholar
• 15. Foletto VS, da Rosa TF, Serafin MB, Bottega A, Hörner R. Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review. Int. J. Antimicrob. Agents 58(3), 106380 (2021). •• Antibacterial activity of paroxetine reported in the literature.
  Medline CASGoogle Scholar
• 16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing (31st ed.). CLSI supplement M100. Clinical and Laboratory Standards Institute, PA, USA (2021).
  Google Scholar
• 17. Do Av Sá LG, Da Silva CR, De A Neto JB et al. Etomidate inhibits the growth of MRSA and exhibits synergism with oxacillin. Future Microbiol. 15(17), 1611–1619 (2020).
  Google Scholar
• 18. Queiroz HA, Da Silva CR, De Andrade Neto JB et al. Synergistic activity of diclofenac sodium with oxacillin against planktonic cells and biofilm of methicillin-resistant Staphylococcus aureus strains. Future Microbiol. 16(6), 375–387 (2021).
  CASGoogle Scholar
• 19. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Tenth Edition. CLSI document M07-A10. Clinical and Laboratory Standards Institute, PA USA (2015).
  Google Scholar
• 20. Andrade Neto JB, Alexandre Josino MA, Rocha da Silva C et al. A mechanistic approach to the in-vitro resistance modulating effects of fluoxetine against meticillin resistant Staphylococcus aureus strains. Microb. Pathog. 127(August 2017), 335–340 (2019). • Fluoxetine, a selective serotonin reuptake inhibitor, also acts against MRSA through membrane damage and DNA fragmentation.
  MedlineGoogle Scholar
• 21. Das B, Mandal D, Dash SK et al. Eugenol provokes ROS-mediated membrane damage-associated antibacterial activity against clinically isolated multidrug-resistant Staphylococcus aureus strains. Infect. Dis. Res. Treat. 9, IDRT.S31741 (2016).
  Google Scholar
• 22. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52(1), 1 (2003).
  Medline CASGoogle Scholar
• 23. Jorge P, Grzywacz D, Kamysz W, Lourenço A, Pereira MO. Searching for new strategies against biofilm infections: colistin-AMP combinations against Pseudomonas aeruginosa and Staphylococcus aureus single- and double-species biofilms. PLoS ONE 12(3), e0174654 (2017).
  MedlineGoogle Scholar
• 24. Shi L, Günther S, Hübschmann T, Wick LY, Harms H, Müller S. Limits of propidium iodide as a cell viability indicator for environmental bacteria. Cytometry A 71(8), 592–598 (2007).
  MedlineGoogle Scholar
• 25. Williams SC, Hong Y, Danavall DCA et al. Distinguishing between living and nonliving bacteria: evaluation of the vital stain propidium iodide and its combined use with molecular probes in aquatic samples. J. Microbiol. Methods 32(3), 225–236 (1998).
  CASGoogle Scholar
• 26. Dwyer DJ, Camacho DM, Kohanski MA, Callura JM, Collins JJ. Antibiotic-induced bacterial cell death exhibits physiological and biochemical hallmarks of apoptosis. Mol. Cell 46(5), 561–572 (2012).
  Medline CASGoogle Scholar
• 27. Csizmadia P. MarvinSketch and MarvinView: molecule applets for the world wide web (2019). https://chemaxon.com/blog/presentation/marvinsketch-and-marvinview-molecule-applets-for-the-world-wide-web
  Google Scholar
• 28. ChemAxon. ‘Marvinafull featured chemical editor for making science accessible on all platforms’ (2019). https://chemaxon.com/marvin
  Google Scholar
• 29. Hanwell MD, Curtis DE, Lonie DC, Vandermeerschd T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4, 17 (2012).
  Medline CASGoogle Scholar
• 30. Lade H, Kim JS. Bacterial targets of antibiotics in methicillin-resistant Staphylococcus aureus. Antibiotics 10(4), 398 (2021).
  CASGoogle Scholar
• 31. Naclerio GA, Sintim HO. Multiple ways to kill bacteria via inhibiting novel cell wall or membrane targets. Future Med. Chem. 12(13), 1253–1279 (2020).
  Medline CASGoogle Scholar
• 32. Moreno LS, Nascimento FB, da Silva CR et al. Activity of arginine–phenylalanine and arginine–tryptophan-based surfactants against Staphylococcus aureus. Future Microbiol. 17(17), 1363–1379 (2022).
  CASGoogle Scholar
• 33. de Andrade Neto JB, Pessoa de Farias Cabral V, Brito Nogueira LF et al. Anti-MRSA activity of curcumin in planktonic cells and biofilms and determination of possible action mechanisms. Microb. Pathog. 155, 104892 (2021).
  MedlineGoogle Scholar
• 34. Fujita J, Maeda Y, Nagao C et al. Crystal structure of FtsA from Staphylococcus aureus. FEBS Lett. 588(10), 1879–1885 (2014).
  Medline CASGoogle Scholar
• 35. Heaslet H, Harris M, Fahnoe K et al. Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.. Proteins 76(3), 706–717 (2009).
  Medline CASGoogle Scholar
• 36. Bax BD, Chan PF, Eggleston DS et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466(7309), 935–940 (2010).
  MedlineGoogle Scholar
• 37. Singh SB, Kaelin DE, Wu J et al. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents – SAR of left-hand-side moiety (Part 2). Bioorg. Med. Chem. Lett. 25(9), 1831–1835 (2015).
  Medline CASGoogle Scholar
• 38. Neidle S, Rayner EL, Simpson IJ et al. Symmetric bis-benzimidazoles: new sequence-selective DNA-binding molecules. Chem. Commun. (10), 929–930 (1999).
  Google Scholar
• 39. Liu C-I, Liu GY, Song Y et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319(5868), 1391–1394 (2008).
  Medline CASGoogle Scholar
• 40. Nguyen T, Kim T, Ta HM et al. Targeting mannitol metabolism as an alternative antimicrobial strategy based on the structure–function study of mannitol-1-phosphate dehydrogenase in Staphylococcus aureus. MBio 10(4), e02660-18 (2019).
  MedlineGoogle Scholar
• 41. Guillet V, Roblin P, Werner S et al. Crystal structure of leucotoxin S component: new insight into the staphylococcal beta-barrel pore-forming toxins. J. Biol. Chem. 279(39), 41028–41037 (2004).
  Medline CASGoogle Scholar
• 42. Foletti D, Strop P, Shaughnessy L et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J. Mol. Biol. 425(10), 1641–1654 (2013).
  Medline CASGoogle Scholar
• 43. Otero LH, Rojas-Altuve A, Llarrull LI et al. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc. Natl Acad. Sci. USA 110(42), 16808–16813 (2013).
  MedlineGoogle Scholar
• 44. Qiu X, Janson CA, Smith WW et al. Crystal structure of Staphylococcus aureus tyrosyl-tRNA synthetase in complex with a class of potent and specific inhibitors. Protein Sci. 10(10), 2008–2016 (2001).
  Medline CASGoogle Scholar
• 45. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455–461 (2009).
  Google Scholar
• 46. Marinho EM, Batista de Andrade Neto J, Silva J et al. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease. Microb. Pathog. 148, 104365 (2020).
  Medline CASGoogle Scholar
• 47. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605–1612 (2004).
  Medline CASGoogle Scholar
• 48. BIOVIA DS. Discovery Studio Modeling Environment, Release 2017, San Diego (2016).
  Google Scholar
• 49. DeLano WL. The PyMOL Molecular Graphics System, Version 2.3 (2020).
  Google Scholar
• 50. da Silva CR, Sá LG do AV, Dos Santos EV et al. Evaluation of the antifungal effect of chlorogenic acid against strains of Candida spp. resistant to fluconazole: apoptosis induction and in silico analysis of the possible mechanisms of action. J. Med. Microbiol. 71(5), 1–17 (2022).
  Google Scholar
• 51. Coutinho TDNP, Barroso FDD, da Silva CR et al. Effects of ketamine in methicillin-resistant Staphylococcus aureus and in silico interaction with sortase A. Can. J. Microbiol. 67(12), 885–893 (2021).
  Medline CASGoogle Scholar
• 52. Sá LG do AV, da Silva CR, Neto JB de A et al. Antifungal activity of etomidate against growing biofilms of fluconazole-resistant Candida spp. strains, binding to mannoproteins and molecular docking with the ALS3 protein. J. Med. Microbiol. 69(10), 1221–1227 (2020).
  MedlineGoogle Scholar
• 53. Hernando-Amado S, Coque TM, Baquero F, Martínez JL. Defining and combating antibiotic resistance from One Health and Global Health perspectives. Nat. Microbiol. 4(9), 1432–1442 (2019).
  Medline CASGoogle Scholar
• 54. Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLOS ONE 12(12), e0189621 (2017).
  MedlineGoogle Scholar
• 55. da Rosa TF, Coelho SS, Foletto VS et al. Alternatives for the treatment of infections caused by ESKAPE pathogens. J. Clin. Pharm. Ther. 45(4), 863–873 (2020).
  MedlineGoogle Scholar
• 56. Hua Y, Dai X, Xu Y et al. Drug repositioning: progress and challenges in drug discovery for various diseases. Eur. J. Med. Chem. 234, 114239 (2022).
  Medline CASGoogle Scholar
• 57. Morales G, Paredes A, Sierra P, Loyola LA. Antimicrobial activity of three Baccharis species used in the traditional medicine of Northern Chile. Molecules 13(4), 790–794 (2008).
  Medline CASGoogle Scholar
• 58. Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov. Today 21(7), 1189–1195 (2016).
  Medline CASGoogle Scholar
• 59. Sanders CC. Ciprofloxacin: in vitro activity, mechanism of action, and resistance. Rev. Infect. Dis. 10(3), 516–527 (1988).
  Medline CASGoogle Scholar
• 60. Durdagi S, Tahir ul Qamar M, Salmas RE, Tariq Q, Anwar F, Ashfaq UA. Investigating the molecular mechanism of staphylococcal DNA gyrase inhibitors: a combined ligand-based and structure-based resources pipeline. J. Mol. Graph. Model. 85, 122–129 (2018).
  Medline CASGoogle Scholar
• 61. Alagumuthu M, Muralidharan VP, Andrew M, Ahmed MH, Iyer SK, Arumugam S. Computational approaches to develop isoquinoline based antibiotics through DNA gyrase inhibition mechanisms unveiled through antibacterial evaluation and molecular docking. Mol. Inform. 37(12), e1800048 (2018).
  MedlineGoogle Scholar
• 62. Majtnerová P, Roušar T. An overview of apoptosis assays detecting DNA fragmentation. Mol. Biol. Rep. 45(5), 1469–1478 (2018).
  Medline CASGoogle Scholar
• 63. Davey HM, Hexley P. Red but not dead? Membranes of stressed Saccharomyces cerevisiae are permeable to propidium iodide. Environ. Microbiol. 13(1), 163–171 (2011).
  Medline CASGoogle Scholar
• 64. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27(1), 1–20 (1997).
  Medline CASGoogle Scholar
• 65. Ochsner UA, Sun X, Jarvis T, Critchley I, Janjic N. Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents. Expert Opin. Investig. Drugs 16(5), 573–593 (2007).
  Medline CASGoogle Scholar
• 66. Kadri S, Direm A, Athmani H, El B, Parlak C. Dual inhibition of S. aureus TyrRS and S. aureus gyrase by two 4-amino-4′-acetyldiphenyl sulfide-based Schiff bases: structural features, DFT study, Hirshfeld surface analysis and molecular docking. Inorg. Chem. Commun. 143(July), 109779 (2022).
  CASGoogle Scholar
• 67. Sun J, Lv PC, Zhu HL. Tyrosyl-tRNA synthetase inhibitors: a patent review. Expert Opin. Ther. Pat. 27(5), 557–564 (2017).
  Medline CASGoogle Scholar
• 68. El-Nabarawi MA, Bendas ER, El Rehem RTA, Abary MYS. Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. Int. J. Pharm. 443(1-2), 307–317 (2013).
  Medline CASGoogle Scholar
• 69. Costa Silva RA, da Silva CR, de Andrade Neto JB et al. In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates. Microb. Pathog. 107, 341–348 (2017). •• Paroxetine does not show cytotoxicity in L929 cells after 72 h of exposure (IC50 > 100 μg/ml).
  MedlineGoogle Scholar
• 70. Parlet CP, Brown MM, Horswill AR. Commensal staphylococci influence Staphylococcus aureus skin colonization and disease. Trends Microbiol. 27(6), 497–507 (2019).
  Medline CASGoogle Scholar
• 71. Yehia FA A, Yousef N, Askoura M. Celastrol mitigates staphyloxanthin biosynthesis and biofilm formation in Staphylococcus aureus via targeting key regulators of virulence; in vitro and in vivo approach. BMC Microbiol. 22(1), 106 (2022).
  Medline CASGoogle Scholar
• 72. Liu GY, Essex A, Buchanan JT et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J. Exp. Med. 202(2), 209–215 (2005).
  Medline CASGoogle Scholar
• 73. Kaatz GW, Moudgal VV, Seo SM, Hansen JB, Kristiansen JE. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. Int. J. Antimicrob. Agents 22(3), 254–261 (2003).
  Medline CASGoogle Scholar
• 74. German N, Kaatz GW, Kerns RJ. Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps. Bioorganic Med. Chem. Lett. 18(4), 1368–1373 (2008).
  Medline CASGoogle Scholar
• 75. Sabatini S, Gosetto F, Manfroni G et al. Evolution from a natural flavones nucleus to obtain 2-(4-propoxyphenyl) quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. J. Med. Chem. 54(16), 5722–5736 (2011).
  Medline CASGoogle Scholar
• 76. Schindler BD, Jacinto P, Kaatz GW. Inhibition of drug efflux pumps in Staphylococcus aureus: current status of potentiating existing antibiotics. Future Microbiol. 8(4), 491–507 (2013).
  CASGoogle Scholar